Last updated: February 14, 2026
Product Overview
NDC 71770-0105 is a biosimilar drug that targets Adalimumab (Humira), used to treat autoimmune conditions such as rheumatoid arthritis and Crohn's disease. It was approved based on the expiration of patent rights for the branded biologic, leading to increased market entry of biosimilars.
Market Size and Growth Drivers
The global adalimumab market was valued at approximately $20 billion in 2021, with biosimilar segments projected to grow at a compound annual growth rate (CAGR) of 20% from 2022 to 2028, driven predominantly by patent expirations, regulatory approvals, and policy shifts favoring biosimilar adoption in the U.S. and EU.
Key factors influencing market growth:
- Patent cliff for Humira occurred in the U.S. in January 2023, opening the market to biosimilar competition.
- Increasing adoption of biosimilars, especially in Medicare and private insurance.
- Cost savings associated with biosimilars, which attract health systems and payers.
Competitive Landscape
NDC 71770-0105 competes directly with other biosimilars entering the market after Humira’s patent expiry. Major competitors include:
- Amgen's Amjevita
- Samsung Bioepis's Hadlima
- Boehringer Ingelheim's Cyltezo
These biosimilars are priced at a 15-30% discount relative to the Humira reference product. The market has seen multiple biosimilars launching simultaneously, creating price competition and pushing down average prices.
Pricing Trends and Projections
Initial biosimilar prices at launch in the U.S. hovered at approximately 25-30% lower than Humira. As competition intensifies, prices are expected to decrease further.
| Timeline |
Approximate Price Discount vs. Humira |
Expected Price Reduction Over 2 Years |
| 2023 (Launch Year) |
25-30% |
Moderate price competition |
| 2024-2025 (Post-Launch) |
35-45% |
Further decline as more biosimilars enter market and reimbursement policies tighten |
Price reductions are subject to payer negotiations, formulary placements, and regional market dynamics.
Regulatory and Policy Impacts
U.S. Centers for Medicare & Medicaid Services (CMS) and private payers advocate for biosimilar use to contain costs. The Biologics Price Competition and Innovation Act (BPCIA) facilitates biosimilar approval pathways, increasing the market’s potential for multiple entries and steep price declines.
Market Entry and Revenue Projections
- First-year sales for NDC 71770-0105 are projected between $200 million and $300 million in the U.S.
- By 2025, sales are expected to reach $500 million, assuming a market share of approximately 20-30%, depending on formulary win rates.
- Price erosion and increased generic competition could cap annual revenue growth at 10-15% during 2024–2026.
Key Factors Affecting Pricing and Market Share
- Insurance coverage policies favoring biosimilar substitution.
- Physician confidence and prescribing practices.
- Payer negotiations and rebates.
- Regional regulatory approvals and patent settlements.
Summary of Risks
- Market penetration risks due to entrenched brand loyalty.
- Delays or barriers in formulary acceptance.
- Potential for biosimilar pricing to overshoot, causing market saturation.
Conclusion
NDC 71770-0105 is positioned in a rapidly expanding biosimilar space with significant price competition. Initial pricing dips are likely but may stabilize as market share consolidates. Long-term revenue depends on market acceptance, regulatory developments, and payer dynamics.
Key Takeaways
- The biosimilar market for adalimumab is expanding, with prices expected to decline 25-45% within two years post-launch.
- Revenue potential in the U.S. for NDC 71770-0105 is projected between $200 million and $500 million in the near term.
- Market competition and payer policies will be critical in determining price stability.
- Regulatory pathways facilitate rapid biosimilar entry, intensifying price competition.
- Long-term success requires strategic formulary positioning and physician adoption.
FAQs
1. What is the main driver behind the price reductions for biosimilars like NDC 71770-0105?
Market competition, increased biosimilar approvals, payer pressure to reduce healthcare costs, and patent expirations drive biosimilar price declines.
2. How does the market share for biosimilars compare to the original biologic?
Biosimilars typically capture 20-50% of the market within 1-3 years of launch, depending on formulary placement and physician acceptance.
3. When will NDC 71770-0105 likely reach peak sales?
Predictions suggest peak sales will occur around 2024–2025, with sales reaching up to $500 million in the U.S.
4. How do regulatory policies influence biosimilar pricing?
Regulatory pathways like BPCIA and policies promoting biosimilar substitution lower market entry barriers, leading to increased competition and price reductions.
5. What factors could impede the growth of NDC 71770-0105?
Entrenched brand loyalty, formulary exclusions, delayed payer acceptance, or regulatory setbacks could limit market penetration.
References
[1] IQVIA, "Global Biosimilars Market Report," 2022.
[2] U.S. Food and Drug Administration, "Biosimilar Approval Pathway," 2022.
[3] CMS.gov, "Medicare and Biosimilar Adoption," 2023.
[4] EvaluatePharma, "Biologics and Biosimilars Market Outlook," 2022.
[5] FDA.gov, "Biologic Price Competition and Innovation Act," 2021.
